Видео ютуба по тегу Stathmin-2

"Stathmin-2: An Emerging Therapeutic Target in TDP-43 Proteinopathies"
2022 Annual ALS ONE Research Symposium: Dr. Kevin Eggan/Stathmin2 Update on biology and therapy.
2022 Annual ALS ONE Research Symposium: Dr. Kevin Eggan/Stathmin2 Update on biology and therapy.
2023 FIRST LOOK | Clotilde Lagier-Tourenne, MD, PhD
2023 FIRST LOOK | Clotilde Lagier-Tourenne, MD, PhD
DNA treatment could delay paralysis that strikes nearly all patients with ALS
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Don Cleveland - Designer DNA Drug Therapy for Neurodegenerative Disease
Don Cleveland - Designer DNA Drug Therapy for Neurodegenerative Disease
The role of TDP-43 in ALS pathology
The role of TDP-43 in ALS pathology
A Novel Therapeutic Target in Neurodegeneration
A Novel Therapeutic Target in Neurodegeneration
Progress in genetic therapies for ALS
Progress in genetic therapies for ALS
UV-Nail Polish Dryers Linked to Cancers, Restoring smile via Facial Nerve Surgery #medicalresearch
UV-Nail Polish Dryers Linked to Cancers, Restoring smile via Facial Nerve Surgery #medicalresearch
Signal transducer & activator of transcription 2 deficiency: a disorder of mitochondrial fission
Signal transducer & activator of transcription 2 deficiency: a disorder of mitochondrial fission
HD101 CME :Module 2 Genetic Factors in HD
HD101 CME :Module 2 Genetic Factors in HD
Tools, Technology & Expertise 2
Tools, Technology & Expertise 2
TNFR2 Taming Regulatory T Cells to Enhance Anti-Tumor Immunity
TNFR2 Taming Regulatory T Cells to Enhance Anti-Tumor Immunity
2024-Dec Investor Webinar: Analysis of Topline Phase 2 DLB Results.
2024-Dec Investor Webinar: Analysis of Topline Phase 2 DLB Results.
Interplay Between TFII-I and TGFβ Signaling Modulate RNA Polymerase II Pausing to Regulate Tumor
Interplay Between TFII-I and TGFβ Signaling Modulate RNA Polymerase II Pausing to Regulate Tumor